公开(公告)号：US20140080891A1

公开(公告)日：2014-03-20

申请号：US14063100

申请日：2013-10-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tsuneo YASUMA ,  Nobuyuki NEGORO ,  Masayuki YAMASHITA ,  Masahiro ITOU

IPC: C07D409/12 ,  C07D307/80

CPC classification number: C07D409/12 ,  C07D307/80

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Abstract translation: 本发明提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。 化合物或其盐或其前药具有GPR40受体功能调节作用，并且可用作胰岛素促分泌素或用于预防或治疗糖尿病等的药剂。

公开(公告)号：US20230102273A1

公开(公告)日：2023-03-30

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro IWATA ,  Masahiro MIZUNO ,  Kazuhiro MAEDA ,  Tsuneo YASUMA ,  Misaki HOMMA ,  Yuya OGURO ,  Naohiro TAYA ,  Lei ZHU ,  John Daniel BAILEY ,  Marianne LANGSTON ,  Siddhesh Dinanath PATIL ,  Shruti GOUR ,  Lilly ROY

IPC: C07D471/08 ,  A61K9/48

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.

公开(公告)号：US20190135852A1

公开(公告)日：2019-05-09

申请号：US16240677

申请日：2019-01-04

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsuru NONOGAWA ,  Toshiaki NAGATA ,  Hideki SAITO ,  Tsuneo YASUMA

IPC: C07H19/207 ,  C07H19/073 ,  C07H19/167 ,  C07H1/00 ,  C07H19/06 ,  C07H21/04 ,  C07H19/067 ,  C07H19/16 ,  C07H21/00

Abstract: In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R1, Y, Base, Z, Ar, R2, R3 and n are each as defined in Claim 1]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method can dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3′-direction but also in the 5′-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide.

公开(公告)号：US20130267589A1

公开(公告)日：2013-10-10

申请号：US13910374

申请日：2013-06-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tsuneo YASUMA ,  Nobuyuki NEGORO

IPC: C07D307/80

CPC classification number: C07D409/12 ,  C07D307/80

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Abstract translation: 本发明提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。 化合物或其盐或其前药具有GPR40受体功能调节作用，并且可用作胰岛素促分泌素或用于预防或治疗糖尿病等的药剂。